Nanomedicine in Cancer Treatment: Mechanisms, Applications, and Future Directions
DOI:
https://doi.org/10.61173/t27ww162Keywords:
Nanomedicine, cancer treatment, targeted drug delivery, multifunctional nanoparticles, clinical applicationsAbstract
Nanomedicine, an emerging field at the intersection of nanotechnology and medicine, holds significant promise for revolutionizing cancer treatment. By utilizing materials at the nanoscale, ranging from 1 to 100 nanometers, nanomedicine offers a versatile platform for targeting tumors, improving drug delivery, and minimizing side effects. This paper explores the design and preparation of nanoparticles, including common materials like liposomes, polymers, metals, and quantum dots, as well as their mechanisms of targeted delivery through both passive and active methods. Key applications of nanomedicine are discussed, particularly in chemotherapy, immunotherapy, and imaging. Clinical progress is highlighted through examples such as FDA-approved drugs like Onivyde for pancreatic cancer and experimental treatments like BIND-014 for metastatic prostate cancer. Despite rapid advancements, significant challenges remain, particularly in scaling up production and ensuring batch consistency. Safety concerns, such as nanoparticle toxicity and unintended accumulation in organs, must be addressed through rigorous testing and design improvements. Ethical considerations and regulatory hurdles also pose obstacles to the widespread clinical adoption of nanomedicine. Looking forward, multifunctionalization and personalized nanomedicine represent key areas of future growth, offering the potential for highly individualized treatments that combine therapeutic and diagnostic capabilities. Continued research and collaboration across scientific disciplines will be crucial in overcoming current limitations and unlocking the full potential of nanomedicine for cancer treatment.
References
[1] Debela, D. T., Muzazu, S. G., Heraro, K. D., Ndalama, M. T., Mesele, B. W., Haile, D. C., Kitui, S. K., & Manyazewal, T. (2021). New approaches and procedures for cancer treatment: Current perspectives. SAGE open medicine, 9, 20503121211034366. https://doi. org/10.1177/20503121211034366
[2] Hulla, J. E., Sahu, S. C., & Hayes, A. W. (2015). N a n o t e c h n o l o g y : H i s t o r y a n d f u t u r e . H u m a n & experimental toxicology, 34(12), 1318–1321. https://doi. org/10.1177/0960327115603588
[3] Malik, S., Muhammad, K., & Waheed, Y. (2023). Emerging Applications of Nanotechnology in Healthcare and Medicine. Molecules (Basel, Switzerland), 28(18), 6624. https://doi. org/10.3390/molecules28186624
[4] Ventola C. L. (2012). The nanomedicine revolution: part 1: emerging concepts. P & T: a peer-reviewed journal for formulary management, 37(9), 512–525.
[5] Wolfram, J., Zhu, M., Yang, Y., Shen, J., Gentile, E., Paolino, D., Fresta, M., Nie, G., Chen, C., Shen, H., Ferrari, M., & Zhao, Y. (2015). Safety of Nanoparticles in Medicine. Current drug targets, 16(14), 1671–1681. https://doi.org/10.2174/1389450115 666140804124808
[6] Xu, M., Han, X., Xiong, H., Gao, Y., Xu, B., Zhu, G., & Li, J. (2023). Cancer Nanomedicine: Emerging Strategies and Therapeutic Potentials. Molecules (Basel, Switzerland), 28(13), 5145. https://doi.org/10.3390/molecules28135145
[7] Dilliard, S.A., Siegwart, D.J. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nat Rev Mater 8, 282–300 (2023). https://doi. org/10.1038/s41578-022-00529-7
[8] Paramasivam, G., Palem, V. V., Sundaram, T., Sundaram, Dean&Francis V., Kishore, S. C., & Bellucci, S. (2021). Nanomaterials: Synthesis and Applications in Theranostics. Nanomaterials (Basel, Switzerland), 11(12), 3228. https://doi.org/10.3390/ nano11123228
[9] Khadka, P., Ro, J., Kim, H., Kim, I., Kim, J. T., Kim, H., Cho, J. M., Yun, G., & Lee, J. (2014). Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability. Asian Journal of Pharmaceutical Sciences, 9(6), 304–316. https://doi.org/10.1016/j.ajps.2014.05.005
[10] Azam, M. A., & Mupit, M. (2022). Carbon nanomaterialbased sensor: Synthesis and characterization. In Elsevier eBooks (pp. 15–28). https://doi.org/10.1016/b978-0-323-91174-0.00015-
[11] Coty, J.-B., & Vauthier, C. (2018). Characterization of nanomedicines: A reflection on a field under construction needed for clinical translation success. Journal of Controlled Release, 254–268. https://doi.org/10.1016/j.jconrel.2018.02.013
[12] Danhier, F., Feron, O., & Préat, V. (2010). To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of Controlled Release, 148(2), 135–146. https://doi.org/10.1016/ j.jconrel.2010.08.027
[13] Sitia, L., Sevieri, M., Signati, L., Bonizzi, A., Chesi, A., Mainini, F., Corsi, F., & Mazzucchelli, S. (2022). HER- 2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment. Cancers, 14(10), 2424. https://doi.org/10.3390/ cancers14102424
[14] Sezgin-Bayindir, Z., Losada-Barreiro, S., Bravo-Díaz, C., Sova, M., Kristl, J., & Saso, L. (2021). Nanotechnology-Based drug delivery to improve the therapeutic benefits of NRF2 modulators in cancer therapy. Antioxidants, 10(5), 685. https:// doi.org/10.3390/antiox10050685
[15] Irvine, D. J., & Dane, E. L. (2020). Enhancing cancer immunotherapy with nanomedicine. Nature reviews. Immunology, 20(5), 321–334. https://doi.org/10.1038/s41577- 019-0269-6
[16] Wu, W., Pu, Y., & Shi, J. (2022). Nanomedicine-enabled chemotherapy-based synergetic cancer treatments. Journal of Nanobiotechnology, 20(1). https://doi.org/10.1186/s12951-021- 01181-z
[17] Karimi Zarchi, A. A., Amini, S. M., Salimi, A., & Kharazi, S. (2018). Synthesis and characterisation of liposomal doxorubicin with loaded gold nanoparticles. IET nanobiotechnology, 12(6), 846–849. https://doi.org/10.1049/iet-nbt.2017.0321
[18] Baker, D. E., & Levien, T. L. (2017). Irinotecan Liposome Injection. Hospital pharmacy, 52(2), 144–150. https://doi. org/10.1310/hpj5202-144
[19] Autio, K. A., Dreicer, R., Anderson, J., Garcia, J. A., Alva, A., Hart, L. L., Milowsky, M. I., Posadas, E. M., Ryan, C. J., Graf, R. P., Dittamore, R., Schreiber, N. A., Summa, J. M., Youssoufian, H., Morris, M. J., & Scher, H. I. (2018). Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial. JAMA oncology, 4(10), 1344–1351. https://doi. org/10.1001/jamaoncol.2018.2168
[20] Bezbaruah, R., Chavda, V. P., Nongrang, L., Alom, S., Deka, K., Kalita, T., Ali, F., Bhattacharjee, B., & Vora, L. (2022). Nanoparticle-Based Delivery Systems for Vaccines. Vaccines, 10(11), 1946. https://doi.org/10.3390/vaccines10111946
[21] Wang, J., Li, Y. & Nie, G. Multifunctional biomolecule nanostructures for cancer therapy. Nat Rev Mater 6, 766–783 (2021). https://doi.org/10.1038/s41578-021-00315-x
[22] Alghamdi, M. A., Fallica, A. N., Virzì, N., Kesharwani, P., Pittalà, V., & Greish, K. (2022). The Promise of Nanotechnology in Personalized Medicine. Journal of personalized medicine, 12(5), 673. https://doi.org/10.3390/jpm12050673
[23] Leong, H. S., Butler, K. S., Brinker, C. J., Azzawi, M., Conlan, S., Dufés, C., Owen, A., Rannard, S., Scott, C., Chen, C., Dobrovolskaia, M. A., Kozlov, S. V., Prina-Mello, A., Schmid, R., Wick, P., Caputo, F., Boisseau, P., Crist, R. M., McNeil, S. E., Fadeel, B., … Pastore, C. (2019). On the issue of transparency and reproducibility in nanomedicine. Nature nanotechnology, 14(7), 629–635. https://doi.org/10.1038/s41565-019-0496-9
[24] Đorđević, S., Gonzalez, M. M., Conejos-Sánchez, I., Carreira, B., Pozzi, S., Acúrcio, R. C., Satchi-Fainaro, R., Florindo, H. F., & Vicent, M. J. (2022). Current hurdles to the translation of nanomedicines from bench to the clinic. Drug delivery and translational research, 12(3), 500–525. https://doi. org/10.1007/s13346-021-01024-2
[25] Soares, S., Sousa, J., Pais, A., & Vitorino, C. (2018). Nanomedicine: Principles, Properties, and Regulatory Issues. Frontiers in chemistry, 6, 360. https://doi.org/10.3389/ fchem.2018.00360
[26] Wasti, S., Lee, I. H., Kim, S., Lee, J., & Kim, H. (2023). Ethical and legal challenges in nanomedical innovations: a scoping review. Frontiers in Genetics, 14. https://doi. org/10.3389/fgene.2023.1163392
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
